[EN] FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE<br/>[FR] COMPOSÉS BICYCLIQUES FUSIONNÉS UTILISÉS COMME INHIBITEURS DE LA PI3 KINASE
申请人:MERCK SERONO SA
公开号:WO2010100144A1
公开(公告)日:2010-09-10
The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.
该发明涉及用于调节磷脂酰肌醇3-激酶活性及相关疾病的化合物(I)的公式。
[EN] 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS<br/>[FR] DERIVES DE 2-CARBOXAMIDE ET 2-SULFONAMIDE-5,6-DIARYL-PYRAZINE SUBSTITUES EN 3, UTILISES COMME MODULATEURS DE CB1
申请人:ASTRAZENECA AB
公开号:WO2004111034A1
公开(公告)日:2004-12-23
The present invention relates to 3-substituted-5,6-diarylpyrazine-2-carboxamide and -2-sulfonamide derivatives and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them. The compounds are cannabinoid receptor 1 (CB1) modulators.
[EN] BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLIQUES BICYCLIQUES ET LEUR UTILISATION COMME INHIBITEURS DE KINASE
申请人:NOVARTIS AG
公开号:WO2009010530A1
公开(公告)日:2009-01-22
Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
A range of 1,3,4‐oxadiazoles have been synthesized using a UV‐B activated flow approach starting from carboxylic acids and 5‐substituted tetrazoles. The application of UV light represents an attractive alternative to the traditional thermolytic approach and has demonstrated comparable efficiency and versatility, with a diverse substrate scope, including the incorporation of highly substituted amino
An efficientroute to construct 2,5-disubstituted tetrazole hemiaminal silylethers via one-pot three-component hemiaminal silylation of 5-substituted tetrazoles, aldehydes, and silyl triflates was developed. Diverse 2,5-disubstituted tetrazole hemiaminal silylethers were obtained with 37 : 63–>99 : 1 regioisomeric ratios. The regioselectivities of this reaction were significantly affected by steric